Synergistic interactions of vancomycin with different antibiotics against escherichia coli: Trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 276-281

  Zhou, Alice ^a   Kang, Tina Manzhu ^a   Yuan, Jessica ^a   Beppler, Casey ^a   Nguyen, Caroline ^a   Mao, Zhiyuan ^a   Nguyen, Minh Quan ^a   Yeh, Pamela ^b   Miller, Jeffrey H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; NITROFURANTOIN; STREPTOMYCIN; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT; CARRIER PROTEIN; ESCHERICHIA COLI PROTEIN; PEPTIDYLPROLYL ISOMERASE; SURA PROTEIN, E COLI;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ESCHERICHIA COLI; GROWTH INHIBITION; MONOTHERAPY; NONHUMAN; WILD TYPE; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; MUTATION;

ANTI-BACTERIAL AGENTS; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; MUTATION; NITROFURANTOIN; PEPTIDYLPROLYL ISOMERASE; TRIMETHOPRIM; VANCOMYCIN;

EID: 84920148375     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03502-14     Document Type: Article

References (40)

1. Nikaido H. 1989. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 33:1831-1836. http://dx .doi.org/10.1128/AAC.33.11.1831.
2. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. 2007. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 45: 3352-3359. http://dx.doi.org/10.1128/JCM.01284-07.
3. Justice SS, Hunstad DA, Harper JR, Duguay AR, Pinkner JS, Bann J, Frieden C, Silhavy TJ, Hultgren SJ. 2005. Periplasmic peptidyl prolyl cis-trans isomerases are not essential for viability, but SurA is required for pilus biogenesis in Escherichia coli. J Bacteriol 187:7680-7686. http://dx .doi.org/10.1128/JB.187.22.7680-7686.2005.
4. Tamae C, Liu A, Kim K, Sitz D, Hong J, Becket E, Bui A, Solaimani P, Tran KP, Yang H, Miller JH. 2008. Determination of antibiotic hypersensitivity among 4,000 single gene knockout mutants of Escherichia coli. J Bacteriol 190:5981-5988. http://dx.doi.org/10.1128/JB.01982-07.
5. Kang TM, Yuan J, Zhou A, Beppler C, Miller JH. 2014. Deoxycytidine deaminase-deficient Escherichia coli strains display acute sensitivity to cy-tidine, adenosine, and guanosine and increased sensitivity to a range of antibiotics, including vancomycin. J Bacteriol 196:1950-1957. http://dx .doi.org/10.1128/JB.01383-13.
6. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame single-gene knockout mutants: the Keio Collection. Mol Syst Biol 2:2006. 0008. http://dx.doi.org/10.1038/msb4100050.
7. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
8. Miller JH. 1992. A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria, p 194-195. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
9. Yeh P, Tschumi AI, Kishony R. 2006. Functional classification of drugs by properties of their pairwise interactions. Nat Genet 28:489-494. http: //dx.doi.org/10.1038/ng1755.
10. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM. 2008. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod 71:1427-1430. http://dx.doi.org/10 .1021/np8002673.
11. Shiu WK, Rahman MM, Curry J, Stapleton P, Zioh M, Malkinson JP, Gibbons S. 2012. Antibacterial acylphloroglucinols from Hypericum olympicum. J Nat Prod 75:336-343. http://dx.doi.org/10.1021/np2003319.
12. Jang KH, Nam SJ, Locke JB, Kauffman CA, Beatty DS, Paul LA, Fenical W. 2013. Anthracimycin, a potent anthrax antibiotic from a marinederived actinomycete. Angew Chem Int Ed Engl 52:7822-7824. http://dx .doi.org/10.1002/anie.201302749.
13. Freitak D, Knorr E, Vogel H, Vilcinskas A. 2012. Gender- and stressorspecific microRNA expression in Tribolium castaneum. Biol Lett 8:308-311. http://dx.doi.org/10.1098/rsbl.2011.0760.
14. Lee RE, Hurdle JG, Liu J, Bruhn DF, Sherman MS, Vaddady PK, Zheng Z, Qi J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, Lee RB, Rakesh, Waidyarachchi SL, Sun D, McNeil MR, Ainsa JA, Boshoff HI, Gonzalez-Juarrero M, Meibohm B, Boettger EC, Lenaerta AJ. 2014. Spectinamidea: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med 20:152-158. http://dx .doi.org/10.1038/nm.3458.
15. Carney DW, Schmitz KR, Truong JV, Sauer RT, Sello J. 2014. Restriction of the conformational dynamics of the cyclic acyldepsipeptide antibiotics improves their antibacterial activity. J Am Chem Soc 136:1922-1929. http://dx.doi.org/10.1021/ja410385c.
16. Geller BL, Greenberg DE. 2014. Peptide-conjugated phosphorodiamidate morpholino oligomers: a new strategy for tackling antibiotic resistance. Ther Deliv 5:243-245. http://dx.doi.org/10.4155/tde.13.145.
17. Cottarel G, Wierzbowski J. 2007. Combination drugs, an emerging option for antibacterial therapy. Trends Biotech 25:547-555. http://dx.doi .org/10.1016/j.tibtech.2007.09.004.
18. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Ishida H, Lee VJ. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45:105-116. http://dx.doi.org/10.1128 /AAC.45.1.105-116.2001.
19. Nelson ML, Levy SB. 1999. Reversal of tetracycline resistance by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 43:1719-1724.
20. Conlon BP, Nakayasu ES, Flack LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503:365-370. http://dx.doi.org/10.1038/nature12790.
21. HuY, Coates AR. 2013. Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin, and chlorhexidine: in vitro and in vivo studies. J Antimicrob Chemother 68:374-384. http://dx.doi.org/10.1093/jac/dks384.
22. Ejim L, Farha MA, Falconer SB, Wildenhain J, Coombes BK, Tyers M, Brown ED, Wright G. 2011. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 7:348-350. http: //dx.doi.org/10.1038/nchembio.559.
23. Marks LR, Clementi EA, Hakansson A. 2012. The human milk proteinlipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agents. PLoS One 7:e43514. http://dx.doi.org/10.1371/journal .pone.0043514.
24. Buynak JD. 2006. Understanding the longevity of the -lactam antibiotics and of antibiotic/ -lactamase inhibitor combinations. Biochem Pharmacol 71:930-940. http://dx.doi.org/10.1016/j.bcp.2005.11.012.
25. Hikida M, Kawashima K, Yoshida M, Mitsuhashi S. 1992. Inactivation of new carbapenem antibiotics by dehydropeptidase-1 from porcine and human renal cortex. J Antimicrob Chemother 30:129-134. http://dx.doi .org/10.1093/jac/30.2.129.
26. Hoffman J, Trimble J, Brophy GM. 2009. Safety of imipenem/cilastin in neurocritical care patients. Neurocrit Care 10:403-407. http://dx.doi.org /10.1007/s12028-008-9170-z.
27. Allison KR, Brynildsen MP, Collins JJ. 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473:216-220. http://dx.doi.org/10.1038/nature10069.
28. Barna JC, Williams DH. 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 38:339-357. http://dx.doi.org/10.1146/annurev.mi.38.100184.002011.
29. Pages JM, James CE, Winterhalter M. 2008. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6:893-903. http://dx.doi.org/10.1038/nrmicro1994.
30. Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ. 2013. Silver enhances antibiotic activity against Gram negative bacteria. Sci Transl Med 5:190ra81. http://dx.doi.org/10.1126/scitranslmed.3006276.
31. Hamoud R, Zimmermann S, Reichling J, Wink M. 2013. Synergistic interactions in two-drug and three drug combinations (thymol, EDTA, and vancomycin) against multi drug resistant bacteria including E. coli. Phytomedicine 21:443-447. http://dx.doi.org/10.1016/j.phymed.2013.10 .016.
32. Kuong KJ, Kuzminov A. 2010. Stalled replication fork repair and misrepair during thymineless death in Escherichia coli. Genes Cells 15:619-634. http://dx.doi.org/10.1111/j.1365-2443.2010.01405.x.
33. Ohkawa T. 1975. Studies of intracellular thymidine nucleotides. Thymineless death and the recovery after re-addition of thymine in Escherichia coli K12. Eur J Biochem 60:57-66.
34. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. http://dx.doi.org/10.1016/j.cell.2007.06.049.
35. Ezraty B, Vergnes A, Banzhaf M, Duverger Y, Huguenot A, Brochado AR, Su SY, Espinosa L, Loiseau L, Py B, Typas A, Barras F. 2013. Fe-S cluster biosynthesis controls uptake of aminoglycosides in a ROS-less death pathway. Science 340:1583-1587. http://dx.doi.org/10.1126/science .1238328.
36. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339:1213-1216. http://dx.doi.org/10.1126/science.1232688.
37. Liu Y, Imlay JA. 2013. Cell death from antibiotics without the involvement of reactive oxygen species. Science 339:1210-1213. http://dx.doi.org /10.1126/science.1232751.
38. Mahoney TF, Silhavy TJ. 2013. The Cpx stress response confers resistance to some, but not all, bactericidal antibiotics. J Bacteriol 195:1869-1874. http://dx.doi.org/10.1128/JB.02197-12.
39. Dwyer DJ, Collins JJ, Walker GC. 10 September 2014. Unraveling the physiological complexities of antibiotic lethality. Annu Rev Pharmacol Toxicol http://dx.doi.org/10.1146/annurev-pharmtox-010814-124712.
40. Tu Y, McCalla DR. 1975. Effect of activated nitrofurans on DNA. Biochim Biophys Acta 402:142-149. http://dx.doi.org/10.1016/0005-2787(75)90032-5.